Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 2 , Pages 180-181 , March 2009

Advancing Alzheimer's disease drug review as a national priority

  • Daniel P. Perry

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: 202-293-2856; Fax: 202-785-8574

References 

  1. Alzheimer's Association. 2008 Alzheimer's disease facts and figures. Alzheimers Dement. 2008;4:110–133
  2. Herbert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimers Dis Assoc Disord. 2001;15:169–173
  3. Herbert LE, Scherr PA, Bienies JL, Bennett DA, Evans DA. Alzheimer disease in the United States population: prevalence estimated using the 2000 census. Arch Neurol. 2003;60:1119–1122
  4. Industry estimates on the number of new AD drug candidates and their potential as disease modifying agents is based on information contained in the following subscription databases. NDA Pipeline, FDC Reports, Inc; Investigational Drugs Database (IDdb3), Thomson Scientific, Ltd; Adis R&D Insight, Adis Data Information BV; IMS R&D Focus, IMS Health; and Pharmaprojects, PJB Publications.

PII: S1552-5260(08)02868-9

doi: 10.1016/j.jalz.2008.08.007

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 2 , Pages 180-181 , March 2009

Article Tools